Placental weight may influence preeclampsia or eclampsia risk through modulating lipid metabolism: a mediation

Zhen Li1, Liang Chen1, Haoan Tang2

  • 1NHC Key Laboratory of Birth Defect for Research and Prevention, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, China.

Insights

Higher placental weight (PW) is linked to reduced preeclampsia/eclampsia (PE/E) risk, potentially mediated by very large high-density lipoprotein (HDL) lipids. This study explores the causal relationship between placental size and PE/E through lipid metabolism.

Area of Science:

  • Obstetrics and Gynecology
  • Metabolic Disorders
  • Genetics

Background:

  • Preeclampsia/eclampsia (PE/E) is a major cause of maternal and perinatal mortality.
  • Abnormal lipid profiles are common in PE/E, but the causal link between placental growth and PE/E risk via lipid metabolism is unclear.

Purpose of the Study:

  • To investigate the causal effect of placental weight (PW) on PE/E risk.
  • To explore the role of lipid metabolism as a mediator in the PW-PE/E relationship.

Main Methods:

  • Two-sample Mendelian randomization (MR) was employed using GWAS data for PW, metabolic biomarkers (NMR), and PE/E.
  • Analyses included PW → PE/E, PW → biomarkers, and biomarker → PE/E, with FDR correction for multiple testing.
  • Mediation analyses used two-step MR and multivariable MR (MVMR) to assess indirect and direct effects.

Main Results:

  • Genetically predicted higher PW was associated with a significantly lower risk of PE/E (OR = 0.52, p = 0.013).
  • PW was linked to specific lipid biomarkers, particularly very large high-density lipoprotein (HDL) components.
  • Mediation analysis suggested partial mediation through very large HDL lipids (e.g., total lipids ~10.4%).

Conclusions:

  • Findings support a protective association between higher PW and reduced PE/E risk.
  • Very large HDL lipid pathways may partially mediate this protective effect.
  • Results provide evidence consistent with mediation, acknowledging MR assumptions and potential overlapping pathways.
Abstract

Related Concept Videos

Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
7.3K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.1K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.4K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K